Loading
A phase 3 trial of Imlunestrant, Tamoxifen and Exemestane in advanced solid tumours, run by Eli Lilly and Company, active and no longer recruiting.
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer is a phase 3 interventional study registered as NCT05514054 by Eli Lilly and Company, with 8000 participants enrolled, started 2022-10-04 and due to reach its primary completion in 2027-10. Interventions recorded: Imlunestrant, Tamoxifen, Anastrozole, Letrozole and Exemestane.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Imlunestrant, Tamoxifen, Eli Lilly (incl. Loxo), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Exemestane, Tamoxifen, UCSF Helen Diller Family Comprehensive Cancer Center, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Exemestane, Tamoxifen, Eli Lilly (incl. Loxo), UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares Exemestane, Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Tamoxifen, Eli Lilly (incl. Loxo), Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/